82 FR 33497 - Pilot Project Program Under the Drug Supply Chain Security Act; Request for Comments
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Food and Drug Administration Federal Register Volume 82, Issue 138 (July 20, 2017)
Food and Drug Administration
Federal Register Volume 82, Issue 138 (July 20, 2017)
| Page Range | 33497-33503 | |
| FR Document | 2017-15203 |
[Federal Register Volume 82, Number 138 (Thursday, July 20, 2017)] [Notices] [Pages 33497-33503] From the Federal Register Online [www.thefederalregister.org] [FR Doc No: 2017-15203] ======================================================================= ----------------------------------------------------------------------- DEPARTMENT OF HEALTH AND HUMAN SERVICES Food and Drug Administration [Docket No. FDA-2016-N-0407] Pilot Project Program Under the Drug Supply Chain Security Act; Request for Comments AGENCY: Food and Drug Administration, HHS. ACTION: Notice; request for comments. ----------------------------------------------------------------------- SUMMARY: The Food and Drug Administration (FDA or Agency) is announcing its intent to establish a pilot project program under the Drug Supply Chain Security Act (the DSCSA Pilot Project Program) to assist in development of the electronic, interoperable system that will identify and trace certain prescription drugs as these are distributed within the United States. Under this program, FDA will work with stakeholders to establish one or more pilot projects to explore and evaluate methods to enhance the safety and security of the pharmaceutical distribution supply chain. Participation in the DSCSA Pilot Project Program will be voluntary and will be open to pharmaceutical distribution supply chain members. FDA will be particularly interested in participation reflecting the diversity of the supply chain, including large and small entities from all industry sectors. This notice describes the proposed DSCSA Pilot Project Program, including proposed instructions for submitting a request to participate. FDA is soliciting comments on the proposed collection of information associated with establishment of the DSCSA Pilot Project Program before submitting the proposed collection to the Office of Management and Budget (OMB) for approval. FDA does not intend to begin the proposed DSCSA Pilot Project Program or accept requests to participate in the program until OMB has approved the proposed collection of information. DATES: Submit written or electronic comments on this pilot project program by September 18, 2017. ADDRESSES: You may submit comments as follows. Please note that late, untimely filed comments will not be considered. Electronic comments must be submitted on or before September 18, 2017. The https://www.regulations.gov electronic filing system will accept comments until midnight Eastern Time at the end of September 18, 2017. Comments received by mail/hand delivery/courier (for written/paper submissions) will be considered timely if they are postmarked or the delivery service acceptance receipt is on or before that date. Electronic Submissions Submit electronic comments in the following way:Federal eRulemaking Portal: https://www.regulations.gov. Follow the instructions for submitting comments. Comments submitted electronically, including attachments, to https://www.regulations.gov will be posted to the docket unchanged. Because your comment will be made public, you are solely responsible for ensuring that your comment does not include any confidential information that you or a third party may not wish to be posted, such as medical information, your or anyone else's Social Security number, or confidential business information, such as a manufacturing process. Please note that if you include your name, contact information, or other information that identifies you in the body of your comments, that information will be posted on https://www.regulations.gov. If you want to submit a comment with confidential information that you do not wish to be made available to the public, submit the comment as a written/paper submission and in the manner detailed (see ``Written/Paper Submissions'' and ``Instructions''). Written/Paper Submissions Submit written/paper submissions as follows: Mail/Hand delivery/Courier (for written/paper submissions): Dockets Management Staff (HFA-305), Food and Drug Administration, 5630 Fishers Lane, Rm. 1061, Rockville, MD 20852. For written/paper comments submitted to the Dockets Management Staff, FDA will post your comment, as well as any attachments, except for information submitted, marked and identified, as confidential, if submitted as detailed in ``Instructions.'' Instructions: All submissions received must include the Docket No. FDA-2016-N-0407 for ``Pilot Project Program under the Drug Supply Chain Security Act; Request for Comments.'' Received comments will be placed in the docket and, except for those submitted as ``Confidential Submissions,'' publicly viewable at https://www.regulations.gov or at the Dockets Management Staff between 9 a.m. and 4 p.m., Monday through Friday. Confidential Submissions--To submit a comment with confidential information that you do not wish to be made publicly available, submit your comments only as a written/paper [[Page 33498]] submission. You should submit two copies total. One copy will include the information you claim to be confidential with a heading or cover note that states ``THIS DOCUMENT CONTAINS CONFIDENTIAL INFORMATION.'' The Agency will review this copy, including the claimed confidential information, in its consideration of comments. The second copy, which will have the claimed confidential information redacted/blacked out, will be available for public viewing and posted on https://www.regulations.gov. Submit both copies to the Dockets Management Staff. If you do not wish your name and contact information to be made publicly available, you can provide this information on the cover sheet and not in the body of your comments and you must identify this information as ``confidential.'' Any information marked as ``confidential'' will not be disclosed except in accordance with 21 CFR 10.20 and other applicable disclosure law. For more information about FDA's posting of comments to public dockets, see 80 FR 56469, September 18, 2015, or access the information at: https://www.thefederalregister.org/fdsys/pkg/FR-2015-09-18/pdf/2015-23389.pdf. Docket: For access to the docket to read background documents or the electronic and written/paper comments received, go to https://www.regulations.gov and insert the docket number, found in brackets in the heading of this document, into the ``Search'' box and follow the prompts and/or go to the Dockets Management Staff, 5630 Fishers Lane, Rm. 1061, Rockville, MD 20852. FOR FURTHER INFORMATION CONTACT: Daniel Bellingham, Office of Compliance, Center for Drug Evaluation and Research, Food and Drug Administration, 10903 New Hampshire Ave., Bldg. 50, Rm. 4285, Silver Spring, MD 20993-0002, 301-796-3130, [email protected]. SUPPLEMENTARY INFORMATION: I. Background On November 27, 2013, the Drug Supply Chain Security Act (DSCSA) (Title II of Pub. L. 113-54) was signed into law. The DSCSA outlines critical steps to build an electronic, interoperable system by November 27, 2023, that will identify and trace certain prescription drugs as they are distributed within the United States. Section 202 of the DSCSA added the new sections 581 and 582 to the Federal Food, Drug, and Cosmetic Act (the FD&C Act) (21 U.S.C. 360eee and 360eee-1, respectively). Under section 582(j) of the FD&C Act, FDA is required to establish one or more pilot projects, in coordination with authorized manufacturers, repackagers, wholesale distributors, and dispensers, to explore and evaluate methods to enhance the safety and security of the pharmaceutical distribution supply chain. FDA will be establishing the DSCSA Pilot Project Program to implement section 582(j) of the FD&C Act. This program will assist the development of the interoperable electronic system to be established by 2023. The new system has the potential to reduce diversion of drugs distributed domestically as well as help reduce the influx of counterfeit drugs from foreign sources. The program will be designed to explore issues related to utilizing the product identifier for product tracing, improving the technical capabilities of the supply chain, identifying the system attributes that are necessary to implement the requirements established under the DSCSA, and any other issues identified by FDA (see section 582(j)(2)(B) of the FD&C Act). Particular program goals include assessing the ability of supply chain members to: Satisfy the requirements of section 582 of the FD&C Act; identify, manage, and prevent the distribution of suspect and illegitimate products as defined in section 581(21) and 581(8) of the FD&C Act, respectively; and demonstrate the electronic, interoperable exchange of product tracing information across the pharmaceutical distribution supply chain, in addition to identifying the system attributes needed to implement the requirements of section 582, particularly the requirement to utilize a product identifier for product tracing and verification purposes. FDA plans to coordinate with stakeholders who reflect the diversity of the pharmaceutical distribution supply chain, including large and small entities from all industry sectors. The pilot project is designed to allow industry to identify and evaluate the most efficient systems for their unique operational systems. II. The Proposed DSCSA Pilot Project Program FDA will be seeking pilot project participants from the pharmaceutical distribution supply chain (authorized manufacturers, repackagers, wholesale distributors, and dispensers) and other stakeholders. FDA expects that participants will propose the design and execution of their pilot project in their submission to FDA; however, FDA intends to meet with all pilot project participants to ensure that the learnings from the pilot project(s) will be complementary in informing the direction of the development of the electronic, interoperable system that will go into effect in 2023. FDA encourages supply chain members to focus their proposed pilot project(s) on the DSCSA requirements related to the interoperable, electronic tracing of products at the package level. Specifically, the pilot project(s) should focus on the requirements for package-level tracing and verification that go into effect in 2023. Such pilot projects will be more useful than pilot projects dedicated to lot-level tracing. If there are adequate pilot project submissions, FDA may establish more than one pilot project to accomplish the goals of the DSCSA Pilot Project Program. A. Products Eligible for Proposed Pilot Projects Proposed pilot projects may include any prescription drug that is a ``product'' within the meaning of section 581(13) of the FD&C Act. At its discretion, FDA may also consider proposed pilot projects involving product types outside the scope of section 581(13) of the FD&C Act (e.g., over-the-counter medicines) that could further the objectives of the DSCSA Pilot Project Program. Each package and homogenous case of product that is part of a pilot project should bear a ``product identifier'' as described in sections 581(14) and 582(a)(9) of the FD&C Act. B. Potential Issues To Examine and Evaluation Methods To Use in Proposed Pilot Projects On April 5 and 6, 2016, FDA held a public workshop entitled ``Proposed Pilot Project(s) under the Drug Supply Chain Security Act (DSCSA).'' This public workshop provided a forum for members of the pharmaceutical distribution supply chain to discuss the design objectives of pilot projects established by FDA under section 582(j) of the FD&C Act. Based on the information gathered at that workshop and from the comments submitted to the public docket for the workshop (Docket No. FDA-2016-N-0407), FDA has identified several potential issues to examine, and evaluation methods to use, in pilot projects established under the DSCSA Pilot Project Program. These potential issues and evaluation methods are summarized in table 1. This table is intended only to assist in the design of potential pilot projects; it does not represent FDA's views or policies regarding the issues described in the table. For ease of reference, the potential issues to examine and evaluation methods have been grouped by focus areas for the pilot projects. [[Page 33499]] Table 1--Potential Issues To Examine and Evaluation Methods To Use in Proposed Pilot Projects ------------------------------------------------------------------------ Potential issues to Potential evaluation Pilot project focus area examine methods ------------------------------------------------------------------------ Product Identifier.......... Processes Impacts of related to the different requirement for representations of manufacturers to the product affix or imprint a identifier on product identifier systems or to each package and processes. homogenous case of --Number of errors. product intended to --Time to process. be introduced in a --Time to reconcile transaction into these differences. commerce. Methods used to issue and manage serial numbers (e.g., including a contract manufacturer's role if applicable or how a repackager associates its product identifier with the product identifier assigned by the original manufacturer). Different representations for the product identifier (e.g., different formats of NDC or serial number). Barcode Quality............. Readability Barcode of barcode printed read error rates. or affixed --Number of items including impact of unnecessarily environmental and quarantined or held human factors. up. Application --Time and resource of linear and 2D impacts. barcodes on product. Distinguishing which barcode to read/use and when. Interoperability............ Process and For both technical decentralized and challenges due to centralized models, variety of time implications. solutions expected --To investigate (e.g., type of suspect and database used and illegitimate system architecture products. for exchanging --For notifications information among required within the trading partners). statutory Maintaining timelines. the integrity of --Related to scaling information up from pilot to contained in the full production. barcode of Product serialized product tracing information throughout the (across multiple distribution supply partners). chain (e.g., a --Capability to trading partner retrieve the goes out of information. business or one --Accuracy of the acquires another information (within business). and between Different systems). methods for exchanging information (e.g., the use of Electronic Data Interchange, Electronic Product Code Information Services, and other solutions separately). Security and access. --Evaluate and document access levels for trading partners. Data/Database/System Issues. Data System quality from Performance and beginning to end of Effectiveness. the product --Time to access and lifecycle and vice use product tracing versa. information, once System that data is performance when received into a full or partially system. loaded with data. Data format --Quality of product or processes for tracing data transfer. information. --Use of technical --Number of breaches standards for to system. defining data --Number of attempts attributes to to breach the enable system that were interoperable prevented or transfers. minimized. --Methods to handle the ``master data'' (product-specific data) and transaction data separately to minimize ``master data'' redundancy. Integration Data and into individual/ product flow. company data --Number of systems. unsuccessful Control and attempts to access access to data by data and trading partners, operational FDA or other impacts. Federal or State --Number of system officials (data interactions within governance). one, and amongst Ability of multiple, trading the system to partners. record product --Time and resource status (e.g., to changes on indicate expired, operations when illegitimate, in data and product error, quarantined) not moving at same at all packaging time (e.g., product levels. arrives before data arrives). --Time for location/ ownership/status changes to be reflected in the system. --Time of product flow delays and associated costs due to system or data problems. Aggregation/Disaggregation.. Multiple Number of levels of adoption system and product of inference, by interactions within different trading one, and amongst partners.. multiple, trading --Impact of partners. inference gaps, Time changes or errors required to conduct in data, aggregate/ particularly disaggregate downstream when operations and searching or transactions. examining the data; how can errors be corrected. Accuracy of aggregation data (measure error counts). Time to gather aggregation/ disaggregation data for investigations and notifications. Time to resolve errors in data. Verification/Notification... Process for Response investigation of times: Current vs. suspect or future process. illegitimate Time needed product, including to obtain product any communication tracing information or coordination. to respond to a --Making and request for responding to verification. verification Time needed requests. to make, respond --Making, to, or terminate a responding, and notification. terminating Time to notifications. gather product --Responding to tracing information requests for to support an information. investigation for a --Testing boundaries suspect or of the system. illegitimate product, or a recall. [[Page 33500]] Percentage of items that are successfully verified vs. those that were targeted for verification. Number of connections/queries needed to gather product tracing information in response to a verification or notification request. Exception Handling/Errors/ Identify Percent Inconsistencies. `honest errors' errors detected: (e.g., over/under compare exceptions shipments, clerical introduced vs. errors or exceptions aggregation errors). detected. Correcting --Identify the first `honest errors'. step in the process where error detected. Number of new or changed processes needed to accomplish DSCSA goals. --Time and resource impacts. `Honest Errors'. --Number of items unnecessarily quarantined and held up. --Time required to detect and correct errors. --Impact on trading partners to correct errors. Barcode read error rates. --Number of items unnecessarily quarantined or held- up. --Time and resource impacts. Special Scenarios........... Situations Error rates when data and for special product do not move processes. together. --Number of items Situations unnecessarily when serialized quarantined or held- product are sold up. and distributed --Time and resource along with non- impacts. serialized product. Accuracy of linkage between original manufacturer product identifier and repackager- issued product identifier. ------------------------------------------------------------------------ FDA also received input from the workshop participants and in the comments submitted to the public docket on factors that the Agency should take into consideration when establishing pilot projects. These factors described in the comments include the extent to which the pilot projects: Represent the mix of products and levels of packaging in the supply chain. Include a diverse set of supply chain stakeholders (types and sizes) and transaction types. Use adaptive design to make the pilot projects more efficient. Target known weaknesses in the supply chain. Can be completed in time to provide useful information for trading partners. Evaluate human factors that could present implementation challenges. Simulate illegitimate products/transactions to test a process or system. Document costs to implement, use, and maintain piloted solutions. Although the Agency intends to take these factors into consideration when establishing pilot projects, FDA also recognizes that a single pilot project is unlikely to satisfy every factor. Accordingly, FDA may establish a pilot project based on a request to participate in the program that does not satisfy one or more of the factors listed in this document. C. Proposed Instructions for Submitting a Request To Participate in the Proposed DSCSA Pilot Project Program Once the DSCSA Pilot Project Program is established, volunteers interested in participating in the DSCSA Pilot Project Program will be able to submit a request to participate by email to a designated FDA email address for the program. For a group of entities that partner to participate in a pilot project, only one submission and one point-of- contact for the proposed pilot project should be provided in the request to participate. Requests to participate may also consider other ideas for a pilot project that are not included in this notice. D. Proposed Content of the Submission for a Request To Participate in the Proposed DSCSA Pilot Project Program The following information should be included in the request: Contact information for the submitter or point of contact, if different from the submitter (name, mailing address, phone number, email address). Names of all partnering entities that would participate in such pilot project (name of company and name of company representative). Type(s) of each partnering entity participating in the pilot project (partnering entities include authorized trading partners or other supply chain stakeholders). Number of employees for each partnering entity that would participate in such pilot project. Proposed start and finish dates of the pilot project. Commitment to start the pilot project within 4 months of receiving a letter of acceptance from FDA. Product(s) that will be used in the pilot project. Location(s) where pilot project will be performed (facility address). Description of the proposed pilot project, including, but not limited to, the goals, objectives, processes that will be studied, and evaluation methods. E. Initiation and Duration of Proposed Pilot Projects The selected participants should be ready to start their pilot project within 4 months of receiving a letter of acceptance from FDA into the program. The duration of a pilot project should not exceed 6 months. FDA may consider a pilot project with a later start date or longer duration depending on the proposed goal(s) and objective(s). Each pilot project is expected to be completed within the proposed duration time period. This time period does not include an additional 30-days for completion of a final report (see section G. Proposed Reports). [[Page 33501]] F. Participation in Proposed Pilot Projects Prior to launching a pilot project, FDA will hold a design strategy meeting with the selected pilot participant(s) to review the goal(s) and objective(s) for the pilot project and discuss the plans and other pertinent details. The participant(s) will be responsible for conducting their pilot project. A group of entities (members of the pharmaceutical distribution supply chain and other stakeholders, including trade associations) that partner to conduct a pilot project may be considered a single participant for purposes of the DSCSA Pilot Project Program. The partners in any pilot project that is selected into the program will be responsible for the funding and resources necessary to conduct the pilot project, and for determining each partner's role and responsibility in their pilot project. Pilot project participants will also be expected to submit reports on the progress of their pilot projects to FDA (see section G. Proposed Reports). Participants should evaluate their pilot project using the evaluation methods they identified during the pilot project design process. G. Proposed Reports Each pilot project is expected to be completed within the proposed duration time period, and participants will be expected to report progress to FDA while the pilot project is being conducted, in addition to a final report within 30 days of completing the pilot project. These reports will provide insight into the systems and process needed to comply with certain DSCSA requirements for enhance drug distribution security. 1. Progress Report(s) Each pilot project program participant is expected to provide reports on the progress of their pilot project to FDA. The progress reports are intended to capture the ongoing work during the pilot project, including but not limited to, current status or results, changes, challenges, and/or lessons learned. FDA will work with participants to develop an appropriate schedule for the submission of progress reports based on the design and duration of the pilot project. Because the duration of a pilot project should not exceed 6 months, the frequency of progress reports will vary based on the length of the individual pilot project. Pilot projects of relatively shorter duration may result in shorter time intervals between progress reports. For example, FDA may ask for monthly progress reports for a 6-month pilot project, however for a one-month pilot project, FDA may ask for weekly progress reports. 2. Final Report Within 30 business days of completing a pilot project, each participant is expected to provide a final report to FDA that captures the description, objectives, methods, evaluation, costs and key findings and lessons learned from the project. Timely completion of pilot project and the final report will support FDA's DSCSA implementation, including the statutory requirements under section 582(j) to consider information from pilot projects in the development of guidances for unit-level tracing and standards for the interoperable data exchange in section 582(h)(3) and (4) of the FD&C Act. FDA may also request that the participants meet with the Agency upon the completion of their pilot project or the final report. H. Proposed Final DSCSA Pilot Project Program Report To ensure that all supply chain members benefit from the information generated by the DSCSA Pilot Project Program, FDA intends to make the following information about each of the program's pilot projects available to the public in a final program report: (1) The names and industry sector(s) of the pilot project participant(s); (2) the pilot project's objectives and evaluation methods; (3) the duration of the pilot project; and (4) the key findings and lessons learned from the pilot project. The information related to the DSCSA Pilot Project Program and the final program report will be posted on FDA's Web site. I. Proposed Recordkeeping Any records generated by a participant for conducting a pilot project should be maintained as an entity would as in a normal course of business. For participants that involve partnering entities, the partnering entities can decide who is responsible for the records generated by conducting a pilot project. FDA recommends that the progress reports and the final report that participants create and submit to FDA for a pilot project should be maintained for at least 1 year after completion of the pilot project. J. Initiation of FDA's DSCSA Pilot Project Program FDA does not intend to begin the proposed DSCSA Pilot Project Program or accept requests to participate in the program until OMB has approved the proposed collection of information described in this notice. III. Paperwork Reduction Act of 1995 Under the Paperwork Reduction Act of 1995 (the PRA) (44 U.S.C. 3501-3520), Federal Agencies must obtain approval from OMB for each collection of information that they conduct or sponsor. ``Collection of information'' is defined in 44 U.S.C. 3502(3) and 5 CFR 1320.3(c) and includes Agency requests or requirements that members of the public submit reports, keep records, or provide information to a third party. Section 3506(c)(2)(A) of the PRA, 44 U.S.C. 3506(c)(2)(A), requires Federal Agencies to provide a 60-day notice in the Federal Register to solicit comment for each proposed collection of information before submitting the collection to OMB for approval. To comply with this requirement, FDA is publishing this notice of the proposed collection of information set forth in this document. With respect to the collection of information associated with the DSCSA Pilot Project Program, FDA invites comments on the following topics: (1) Whether the proposed information collected is necessary for the proper performance of FDA's functions, including whether the information will have practical utility; (2) the accuracy of FDA's estimated burden of the proposed information collected, including the validity of the methodology and assumptions used; (3) ways to enhance the quality, utility, and clarity of the information collected; and (4) ways to minimize the burden of information collected on the respondents, including through the use of automated collection techniques, when appropriate, and other forms of information technology. The estimated burden for the information collection associated with the DSCSA Pilot Project Program consists of the following: Submitting a request to participate and reporting activities. FDA estimates that no more than 10 respondents (i.e., the submitter or point of contact identified on the request to participate) will submit a request to participate, and that it will take approximately 80 hours to complete a request and submit the request to FDA. FDA estimates that certain respondents will coordinate with partnering entities to submit a request to participate; the burden estimate associated with that coordination follows. FDA estimates that it will select no more than eight participants for the pilot program. The estimated total time for respondents to submit a request to participate in the program is 800 hours. Once the request [[Page 33502]] to participate is accepted, the submitter is now a participant of the DSCSA Pilot Project Program. FDA estimates that the eight respondents (i.e., participants) will submit an average of five progress reports to FDA. Because the duration of a pilot project should not exceed 6 months, the frequency of progress reports will vary based on the length of the individual pilot project. Pilot projects of relatively shorter duration may result in shorter time intervals between progress reports so that the reports will be sufficient to capture progress while the pilot project is ongoing. FDA estimates that it will take approximately 8 hours to compile and submit each progress report. The estimated total number of hours for submitting progress reports would be 320 hours. After completion of their pilot project, each respondent will provide one final report to FDA. FDA estimates that it will take the eight respondents approximately 40 hours to submit a final report. The estimated total number of hours for submitting the final report is 320 hours. The total hours for the estimated reporting burden are 1,440 hours (table 2). Recordkeeping activities. Recordkeeping activities include storing and maintaining records related to submitting a request to participate in the program and compiling reports. Respondents can use current record retention capabilities for electronic or paper storage to achieve these activities. FDA estimates that no more than 10 respondents will have recordkeeping activities related to program participation. FDA believes that it will take 0.5 hour/year to ensure that the documents related to submitting a request to participate in the program are retained properly for a minimum of 1 year after the pilot project is completed (as recommended by FDA). The resulting total to maintain the records related to submitting a request is 5 hours annually. For retaining records related to progress reports and the final report properly for a minimum of 1 year after the pilot project is completed (as recommended by FDA), FDA estimates that it will take approximately 0.5 hour/year. As noted previously, FDA estimates that the eight respondents will submit an average of five progress reports and one final report to FDA. The estimated total for maintaining progress reports and the final report is 20 and 4 hours, respectively. The total recordkeeping burden is estimated to be 29 hours (table 3). In developing its burden estimate for records associated with the proposed pilot projects, FDA has taken account of existing industry practices for keeping records in the normal course of their business. In particular, FDA is aware of various supply chain stakeholders that have conducted pilot projects over the past few years, including some pilot projects that occurred before the DSCSA was enacted. These pilot projects covered topics related to serialization, movement of product data, aggregation of data, and verification of product identifiers of returned products. Members of the supply chain who conduct pilot projects of their own accord created associated records as a matter of usual and customary business practice. Therefore, the burden estimates for like records associated with the proposed FDA pilot project program are not included in the calculation of the recordkeeping burden (see 5 CFR 1320.3(b)(2)). FDA welcomes comments on the activities identified for conducting a pilot project that FDA considers to be usual and customary business practice. Third-party disclosure activities. For those pilot projects that involve a participant composed of partnering entities in the program, FDA is taking into consideration the time that partnering entities will spend coordinating with each other in a pilot project. For the initial request to participate, FDA estimates that eight respondents will work with their respective partnering entities, and the average number of partnering entities will be two. FDA estimates that each respondent will spend 8 hours coordinating with each partnering entity. Thus, for eight respondents with an average of two partnering entities, the estimated total burden for coordinating with partnering entities related to the submission of the request to participate in the program is 128 hours. FDA estimates that seven respondents will need to coordinate with an average of two partnering entities to create progress reports and the final report to submit to FDA. Earlier, FDA estimated that an average of five progress reports will be submitted to FDA per respondent. If a respondent has an average of 2 partners, it will coordinate 10 times with those partners on the progress reports. FDA estimates that for each progress report, it will take 4 hours to coordinate with each partner, resulting in a total of 280 hours. FDA estimates that for each final report, it will take approximately 20 hours to coordinate with each partner, resulting in a total of 280 hours. The total estimation for third-party disclosure burden is 688 hours (table 4). Table 2--Estimated Reporting Burden \1\ ---------------------------------------------------------------------------------------------------------------- Number of DSCSA pilot project program Number of responses per Total Hours per Total hours respondents respondent responses response ---------------------------------------------------------------------------------------------------------------- Requests to participate...... 10 1 10 80 800 Progress reports............. 8 5 40 8 320 Final report to FDA.......... 8 1 8 40 320 ---------------------------------------------------------------------------------- Total.................... ................. .............. .............. .............. 1,440 ---------------------------------------------------------------------------------------------------------------- \1\ There are no capital costs or operating and maintenance costs associated with this collection of information. Table 3--Recordkeeping Burden \1\ -------------------------------------------------------------------------------------------------------------------------------------------------------- Number of DSCSA Pilot project program Number of records per Total records Hours per record Total hours recordkeepers recordkeeper -------------------------------------------------------------------------------------------------------------------------------------------------------- Records related to requests to participate... 10 1 10 0.5 (30 minutes)...................... 5 Records related to progress reports.......... 8 5 40 0.5 (30 minutes)...................... 20 Records related to the final report to FDA... 8 1 8 0.5 (30 minutes)...................... 4 ---------------------------------------------------------------------------------------------------------- [[Page 33503]] Total.................................... ................. .............. .............. ...................................... 29 -------------------------------------------------------------------------------------------------------------------------------------------------------- \1\ There are no capital costs or operating and maintenance costs associated with this collection of information. Table 4--Third-Party Disclosure Burden \1\ ---------------------------------------------------------------------------------------------------------------- Number of DSCSA pilot project program Number of disclosures Total Hours per Total hours respondents per respondent disclosures disclosure ---------------------------------------------------------------------------------------------------------------- Coordination with partnering 8 2 16 8 128 entities related to requests to participate.............. Coordination with partnering 7 10 70 4 280 entities related to progress reports..................... Coordination with partnering 7 2 14 20 280 entities related to final reports..................... ---------------------------------------------------------------------------------- Total.................... ................. .............. .............. .............. 688 ---------------------------------------------------------------------------------------------------------------- \1\ There are no capital costs or operating and maintenance costs associated with this collection of information. Dated: July 14, 2017. Anna K. Abram, Deputy Commissioner for Policy, Planning, Legislation, and Analysis. [FR Doc. 2017-15203 Filed 7-19-17; 8:45 am] BILLING CODE 4164-01-P
![Federal Register / Vol. 82, No. 138 / Thursday, July 20, 2017 / Notices 33497
the securities transactions conducted by DEPARTMENT OF HEALTH AND submissions) will be considered timely
or on behalf of the account were HUMAN SERVICES if they are postmarked or the delivery
undertaken by the bank in the exercise service acceptance receipt is on or
of its trust or fiduciary responsibilities Food and Drug Administration before that date.
with respect to the account. [Docket No. FDA–2016–N–0407] Electronic Submissions
Section 741. Section 741(a)(2)(ii)(A) Submit electronic comments in the
requires a bank relying on this Pilot Project Program Under the Drug
following way:
exemption, which permits banks to Supply Chain Security Act; Request for
• Federal eRulemaking Portal:
effect transactions in the shares of a Comments
https://www.regulations.gov. Follow the
money market fund, to provide AGENCY: Food and Drug Administration, instructions for submitting comments.
customers with a prospectus for the HHS. Comments submitted electronically,
money market fund securities, not later including attachments, to https://
ACTION: Notice; request for comments.
than the time the customer authorizes www.regulations.gov will be posted to
the bank to effect the transaction in such SUMMARY: The Food and Drug the docket unchanged. Because your
securities, if the class or series of Administration (FDA or Agency) is comment will be made public, you are
securities are not no-load. In situations announcing its intent to establish a pilot solely responsible for ensuring that your
where a bank effects transactions under project program under the Drug Supply comment does not include any
the exemption as part of a program for Chain Security Act (the DSCSA Pilot confidential information that you or a
the investment or reinvestment of Project Program) to assist in third party may not wish to be posted,
deposit funds of, or collected by, development of the electronic, such as medical information, your or
another bank, the Section permits either interoperable system that will identify anyone else’s Social Security number, or
the effecting bank or the deposit-taking and trace certain prescription drugs as confidential business information, such
bank to provide the customer a these are distributed within the United as a manufacturing process. Please note
prospectus for the money market fund States. Under this program, FDA will that if you include your name, contact
securities. work with stakeholders to establish one information, or other information that
or more pilot projects to explore and identifies you in the body of your
Legal authorization and
evaluate methods to enhance the safety comments, that information will be
confidentiality: The Board’s Legal
and security of the pharmaceutical posted on https://www.regulations.gov.
Division has determined that section • If you want to submit a comment
distribution supply chain. Participation
3(a)(4)(F) of the Exchange Act (15 U.S.C. with confidential information that you
in the DSCSA Pilot Project Program will
78c(a)(4)(F)) authorizes the Board and do not wish to be made available to the
be voluntary and will be open to
the SEC to require the information public, submit the comment as a
pharmaceutical distribution supply
collection. The FR 4025 is required to chain members. FDA will be written/paper submission and in the
obtain a benefit because banks wishing particularly interested in participation manner detailed (see ‘‘Written/Paper
to utilize exemptions provided by the reflecting the diversity of the supply Submissions’’ and ‘‘Instructions’’).
rules 701, 723, and 741 are required to chain, including large and small entities
comply with the recordkeeping and Written/Paper Submissions
from all industry sectors. This notice
disclosure requirements. If an describes the proposed DSCSA Pilot Submit written/paper submissions as
institution considers the information to Project Program, including proposed follows:
be trade secrets and/or privileged, such instructions for submitting a request to • Mail/Hand delivery/Courier (for
information could be withheld from the participate. FDA is soliciting comments written/paper submissions): Dockets
public under section (b)(4) of the on the proposed collection of Management Staff (HFA–305), Food and
Freedom of Information Act (5 U.S.C. information associated with Drug Administration, 5630 Fishers
552(b)(4)). Additionally, to the extent establishment of the DSCSA Pilot Lane, Rm. 1061, Rockville, MD 20852.
that such information may be contained • For written/paper comments
Project Program before submitting the
in an examination report, such submitted to the Dockets Management
proposed collection to the Office of
information maybe also be withheld Staff, FDA will post your comment, as
Management and Budget (OMB) for
from the public under section (b)(8) of well as any attachments, except for
approval. FDA does not intend to begin
the Freedom of Information Act (5 information submitted, marked and
the proposed DSCSA Pilot Project
U.S.C. 552 (b)(8)). identified, as confidential, if submitted
Program or accept requests to
as detailed in ‘‘Instructions.’’
Current Actions: On April 3, 2017, the participate in the program until OMB
Instructions: All submissions received
Board published a notice in the Federal has approved the proposed collection of
must include the Docket No. FDA–
Register (82 FR 16210) requesting information.
2016–N–0407 for ‘‘Pilot Project Program
public comment for 60 days on the DATES: Submit written or electronic under the Drug Supply Chain Security
extension, without revision, of the comments on this pilot project program Act; Request for Comments.’’ Received
Recordkeeping and Disclosure by September 18, 2017. comments will be placed in the docket
Requirements Associated with ADDRESSES: You may submit comments and, except for those submitted as
Regulation R. The comment period for as follows. Please note that late, ‘‘Confidential Submissions,’’ publicly
this notice expired on June 2, 2017. The
asabaliauskas on DSKBBXCHB2PROD with NOTICES
untimely filed comments will not be viewable at https://www.regulations.gov
Board did not receive any comments. considered. Electronic comments must or at the Dockets Management Staff
Board of Governors of the Federal Reserve be submitted on or before September 18, between 9 a.m. and 4 p.m., Monday
System, July 17, 2017. 2017. The https://www.regulations.gov through Friday.
electronic filing system will accept • Confidential Submissions—To
Ann E. Misback
comments until midnight Eastern Time submit a comment with confidential
Secretary of the Board. at the end of September 18, 2017. information that you do not wish to be
[FR Doc. 2017–15263 Filed 7–19–17; 8:45 am] Comments received by mail/hand made publicly available, submit your
BILLING CODE 6210–01–P delivery/courier (for written/paper comments only as a written/paper
VerDate Sep<11>2014 18:50 Jul 19, 2017 Jkt 241001 PO 00000 Frm 00022 Fmt 4703 Sfmt 4703 E:\FR\FM\20JYN1.SGM 20JYN1](https://thefederalregister.org/doc/82_FR_33635/page/1.svg)
![Federal Register / Vol. 82, No. 138 / Thursday, July 20, 2017 / Notices 33503
TABLE 3—RECORDKEEPING BURDEN 1—Continued
Number of
Number of
DSCSA Pilot project program records per Total records Hours per record Total hours
recordkeepers recordkeeper
Total ................................................................. .............................. ........................ ........................ .............................. 29
1 There are no capital costs or operating and maintenance costs associated with this collection of information.
TABLE 4—THIRD-PARTY DISCLOSURE BURDEN 1
Number of
Number of disclosures Total Hours per
DSCSA pilot project program Total hours
respondents per disclosures disclosure
respondent
Coordination with partnering entities related to re-
quests to participate ................................................... 8 2 16 8 128
Coordination with partnering entities related to
progress reports ......................................................... 7 10 70 4 280
Coordination with partnering entities related to final re-
ports ............................................................................ 7 2 14 20 280
Total ........................................................................ .............................. ........................ ........................ ........................ 688
1 There are no capital costs or operating and maintenance costs associated with this collection of information.
Dated: July 14, 2017. either electronic or written comments including attachments, to https://
Anna K. Abram, on the public meeting by November 20, www.regulations.gov will be posted to
Deputy Commissioner for Policy, Planning, 2017. See the SUPPLEMENTARY the docket unchanged. Since your
Legislation, and Analysis. INFORMATION section for registration date comment will be made public, you are
[FR Doc. 2017–15203 Filed 7–19–17; 8:45 am] and information. solely responsible for ensuring that your
BILLING CODE 4164–01–P ADDRESSES: The public meeting will be comment does not include any
held at the FDA White Oak Campus, confidential information that you or a
10903 New Hampshire Ave., Bldg. 31 third party may not wish to be posted,
DEPARTMENT OF HEALTH AND Conference Center, the Great Room (Rm. such as medical information, your or
HUMAN SERVICES 1503), Silver Spring, MD 20993. anyone else’s Social Security number, or
Entrance for the public meeting confidential business information, such
Food and Drug Administration participants (non-FDA employees) is as a manufacturing process. Please note
[Docket No. FDA–2017–N–3068] through Building 1, where routine that if you include your name, contact
security check procedures will be information, or other information that
Patient-Focused Drug Development for performed. For parking and security identifies you in the body of your
Hereditary Angioedema; Public information, please refer to https:// comments, that information will be
Meeting; Request for Comments www.fda.gov/AboutFDA/ posted on https://www.regulations.gov.
WorkingatFDA/BuildingsandFacilities/ • If you want to submit a comment
AGENCY: Food and Drug Administration, WhiteOakCampusInformation/ with confidential information that you
HHS. ucm241740.htm. do not wish to be made available to the
ACTION: Notice of public meeting; You may submit comments as public, submit the comment as a
request for comments. follows. Please note that late, untimely written/paper submission and in the
filed comments will not be considered. manner detailed (see ‘‘Written/Paper
SUMMARY: The Food and Drug Electronic comments must be submitted Submissions’’ and ‘‘Instructions’’).
Administration (FDA, the Agency, or on or before November 20, 2017. The
we) is announcing a public meeting and Written/Paper Submissions
https://www.regulations.gov electronic
an opportunity for public comment on filing system will accept comments Submit written/paper submissions as
‘‘Patient-Focused Drug Development for until midnight Eastern Time at the end follows:
Hereditary Angioedema.’’ Patient- of November 20, 2017. Comments • Mail/Hand delivery/Courier (for
Focused Drug Development is part of received by mail/hand delivery/courier written/paper submissions): Dockets
FDA’s performance commitment under (for written/paper submissions) will be Management Staff (HFA–305), Food and
the fifth authorization of the considered timely if they are Drug Administration, 5630 Fishers
Prescription Drug User Fee Act (PDUFA postmarked or the delivery service Lane, Rm. 1061, Rockville, MD 20852.
V). The public meeting is intended to acceptance receipt is on or before that • For written/paper comments
allow FDA to obtain patients’
asabaliauskas on DSKBBXCHB2PROD with NOTICES
date. submitted to the Dockets Management
perspectives on the impact of hereditary Staff, FDA will post your comment as
angioedema (HAE) on daily life. FDA Electronic Submissions well as any attachments, except for
also is seeking patients’ views on Submit electronic comments in the information submitted, marked and
treatment approaches for HAE. following way: identified, as confidential, if submitted
DATES: The public meeting will be held • Federal eRulemaking Portal: as detailed in ‘‘Instructions.’’
on September 25, 2017, from 9 a.m. to https://www.regulations.gov. Follow the Instructions: All submissions received
3 p.m. Registration to attend must be instructions for submitting comments. must include the Docket No. FDA–
received by August 10, 2017. Submit Comments submitted electronically, 2017–N–3068 for ‘‘Patient-Focused Drug
VerDate Sep<11>2014 18:50 Jul 19, 2017 Jkt 241001 PO 00000 Frm 00028 Fmt 4703 Sfmt 4703 E:\FR\FM\20JYN1.SGM 20JYN1](https://thefederalregister.org/doc/82_FR_33635/page/7.svg)
Document Created: 2017-07-20 06:57:50
Document Modified: 2017-07-20 06:57:50
| Category | Regulatory Information | |
| Collection | Federal Register | |
| sudoc Class | AE 2.7: GS 4.107: AE 2.106: | |
| Publisher | Office of the Federal Register, National Archives and Records Administration | |
| Section | Notices | |
| Action | Notice; request for comments. | |
| Dates | Submit written or electronic comments on this pilot project program by September 18, 2017. | |
| Contact | Daniel Bellingham, Office of Compliance, Center for Drug Evaluation and Research, Food and Drug Administration, 10903 New Hampshire Ave., Bldg. 50, Rm. 4285, Silver Spring, MD 20993-0002, 301-796-3130, [email protected] | |
| FR Citation | 82 FR 33497 |
2025 Federal Register | Disclaimer | Privacy Policy
USC | CFR | eCFR